4//SEC Filing
Heffernan Mark 4
Accession 0001572426-17-000026
CIK 0001618561other
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 9:30 PM ET
Size
22.4 KB
Accession
0001572426-17-000026
Insider Transaction Report
Form 4
Heffernan Mark
Chief Executive Officer
Transactions
- Disposition to Issuer
Restricted Share Units
2017-07-31$6.59/sh−50,000$329,750→ 0 totalExercise: $0.13Exp: 2020-07-01→ Ordinary Shares (50,000 underlying) - Disposition to Issuer
Ordinary Shares
2017-07-31$6.72/sh−109,810$737,923→ 0 total - Disposition to Issuer
Option to Purchase Ordinary Shares
2017-07-31$6.59/sh−4,833$31,874→ 0 totalExercise: $0.13Exp: 2019-07-01→ Ordinary Shares (4,833 underlying) - Disposition to Issuer
Option to Purchase Ordinary Shares
2017-07-31$0.37/sh−52,040$19,255→ 0 totalExercise: $6.35Exp: 2019-02-28→ Ordinary Shares (52,040 underlying) - Disposition to Issuer
Ordinary Shares
2017-07-31$6.72/sh−243,587$1,636,905→ 0 total(indirect: By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C>) - Disposition to Issuer
Restricted Share Units
2017-07-31$6.59/sh−106,929$705,197→ 0 totalExercise: $0.13Exp: 2020-07-01→ Ordinary Shares (106,929 underlying) - Disposition to Issuer
Option to Purchase Ordinary Shares
2017-07-31$6.59/sh−9,203$60,694→ 0 totalExercise: $0.13Exp: 2020-11-05→ Ordinary Shares (9,203 underlying) - Disposition to Issuer
Option to Purchase Ordinary Shares
2017-07-31−100,000→ 0 totalExercise: $15.00Exp: 2020-05-18→ Ordinary Shares (100,000 underlying)
Footnotes (8)
- [F1]Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer.
- [F2]The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
- [F3]This restricted share unit, which would have vested and become convertible as to 25,000 shares on each of 7/1/18 and 7/1/19, in each case subject to payment of the nominal value per share of $0.125 to the Issuer within 30 days of vesting, was cancelled in the Acquisition in exchange for a cash payment equal to $329,750. This amount represents the difference between such nominal value per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on conversion of the restricted share unit.
- [F4]This restricted share unit, which would have vested and become convertible as to 35,643 shares on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share of $0.125 to the Issuer within 30 days of vesting, was cancelled in the Acquisition in exchange for a cash payment equal to $705,196.76. This amount represents the difference between such nominal value per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on conversion of the restricted share unit.
- [F5]This option, which was fully vested, was cancelled in the Acquisition in exchange for a cash payment equal to $31,873.64, representing the difference between the exercise price of $0.125 per share and the $6.72 consideration per share payable in connection with in the Acquisition multiplied by the number of shares issuable on exercise of the option.
- [F6]This option, which was fully vested, was cancelled in the Acquisition in exchange for a cash payment equal to $60,693.79, representing the difference between the exercise price of $0.125 per share and the $6.72 consideration per share payable in connection with in the Acquisition multiplied by the number of shares issuable on exercise of the option.
- [F7]This option, which was fully vested, was cancelled in the Acquisition in exchange for a cash payment equal to $19,254.80, representing the difference between the exercise price of $6.35 per share and the $6.72 consideration per share payable in connection with in the Acquisition multiplied by the number of shares issuable on exercise of the option.
- [F8]This option, which was vested as to 70,000 shares and would have vested as to 5,000 shares on each of 9/30/17, 12/31/17, 3/31/18, 6/30/18, 9/30/18 and 12/31/18, was cancelled in the Acquisition in exchange for no cash payment because the $15.00 exercise price per share exceeded the $6.72 consideration per share payable in connection with in the Acquisition.
Documents
Issuer
Nexvet Biopharma plc
CIK 0001618561
Entity typeother
Related Parties
1- filerCIK 0001632439
Filing Metadata
- Form type
- 4
- Filed
- Aug 1, 8:00 PM ET
- Accepted
- Aug 2, 9:30 PM ET
- Size
- 22.4 KB